

Neurotech

US clinical trial/investor webinar

Perth, Australia & Malta – 10 July 2018 – Neurotech International Limited (ASX:NTI) (“Neurotech” or the “Company”), developer of quality medical solutions improving the lives of children with autism, invites shareholders and interested parties to join Chief Executive Officer Wolfgang Storf and its US clinical trial Lead Investigator Professor Frederick Carrick for a webinar regarding the recently announced results of the trial.

Professor Carrick is a Professor of Neurology and Senior Research Fellow of BCMHR in association with the University of Cambridge, Cambridge UK. During his career Professor Carrick has been a Global Clinical Scholar at Harvard Medical School and is a Faculty Scholar at Harvard Medical School’s Harvard Macy Institute. He has maintained a consultant specialist practice in neurology for four decades and has been a medical educator for 38 years. He is the subject of the Emmy award-winning PBS documentary ‘Waking up the Brain’ as well as countless television, newspaper, magazine and journal articles.

During the webinar Mr Storf and Professor Carrick will provide comment on the findings observed during the Mente Autism trial, their significance in the world of autism and how this will help Neurotech as it pursues increased sales of Mente Autism and potential FDA clearance.

Mr Storf and Professor Carrick will also address questions, which can be submitted in advance of the call to matt@nwrcommunications.com.au

The webinar is scheduled for Thursday 12 July at 9am AEST (7am AWST / Wednesday 11pm GMT).

To connect, please use the following weblink, where participants can also register in advance. Alternatively, participants can join in audio-only mode on the below dial-in numbers.

WEBLINK:

<https://attendee.gotowebinar.com/register/6810929568269084674>

DIAL-IN:

Australia: +61 3 8488 8990

UK: +44 330 221 9922

USA: +1 562 247 8421

Italy: +39 0 230 57 81 73

Access code: 167 009 590

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com

accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder. Designed for home use, it helps relax the minds of children on the spectrum which in turn helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420